News > Clearmind Medicine Inc. scores milestone patent issuance to expedite and protect psychedelic-based treatment for AUD ($CMND)

Clearmind Medicine Inc. scores milestone patent issuance to expedite and protect psychedelic-based treatment for AUD ($CMND)

Clearmind Medicine Inc. has taken a giant step forward in its mission to deliver a first-to-market psychedelic-based treatment targeting Alcohol Use Disorder (AUD). Last Wednesday, CMND announced being granted a patent from the United States Patent and Trademark Office (USPTO) to use its proprietary MEAI as an alcoholic beverage substitute.